Alembic Pharmas Karakhadi facility gets EIR

Alembic Pharmaceuticals announced that the company’s API facility located at Karakhadi has received Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA).

The regulatory authority carried out the inspection from January 13 to 17, 2020 at the facility. USFDA recently concluded its inspection at Alembic Pharmaceuticals General Oral Solid Formulation Facility located in Panelav (Gujarat) and issued a form 483 with four procedural observations. The company has also received a final approval for its Abbreviated New Drug Application (ANDA) Doxycycline Hyclate Tablets USP, 20 mg, indicated for use as an adjunct to scaling and root planing in order to promote attachment level gain and also, to reduce pocket depth in patients with adult periodontitis.

The company also declared an interim dividend of Rs 7 per equity share for FY19-20. Additionally, it also announced a special dividend of Rs 3 per equity share for FY19-20.

Alembic Pharmaceuticals Ltd is a multinational pharmaceutical company headquartered in Vadodara (Gujarat). It is involved in the manufacture of pharmaceutical products, substances and intermediates.

On Tuesday, the stock of the company was trading at Rs 531.80, up by mere 0.13 per cent or Rs 1.90 per share. The scrip opened at Rs 542 and reached an intraday high of Rs 550.55 and intraday low of Rs 523.50. The 52-week high is Rs 682.50 and 52-week low is Rs 435.10 on BSE.